Literature DB >> 19752761

Submaximal exercise coronary artery flow increases in postmenopausal women without coronary artery disease after estrogen and atorvastatin.

Chirapa Puntawangkoon1, Tim M Morgan, David M Herrington, Craig A Hamilton, W Gregory Hundley.   

Abstract

OBJECTIVE: The aim of this study was to determine the effect of statins and hormone therapy on submaximal exercise-induced coronary artery blood flow in postmenopausal women without a history of coronary artery disease. Hormone therapy or statin therapy in early postmenopausal women without coronary artery disease has been shown to enhance arterial endothelial function; we hypothesized that these agents would improve submaximal exercise-induced coronary artery blood flow.
METHODS: Sixty-four postmenopausal women, aged 50 to 65 years without documented coronary artery disease, were randomized in a double-blind, crossover fashion to receive 8 weeks of hormone therapy versus placebo, with or without 80 mg/day of atorvastatin. Before receipt of any therapy and after each treatment period, each woman underwent measures of coronary artery blood flow at rest and stress.
RESULTS: The combination of hormone therapy and atorvastatin increased submaximal exercise-induced coronary artery blood flow (P = 0.04). In the subgroups of women compliant with treatment, resting coronary artery blood flow increased in those receiving hormone therapy (P = 0.03) or statin therapy (P = 0.02).
CONCLUSIONS: In postmenopausal women aged 50 to 65 years without documented coronary artery disease, resting and submaximal exercise-induced coronary artery blood flow improves after receipt of high-dose atorvastatin and conjugated estrogens therapy.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19752761      PMCID: PMC2806513          DOI: 10.1097/gme.0b013e3181b63c4d

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  29 in total

1.  Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation.

Authors:  A H Wagner; T Köhler; U Rückschloss; I Just; M Hecker
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-01       Impact factor: 8.311

2.  Is LDL-C passed its prime? The emerging role of non-HDL, LDL-P, and ApoB in CHD risk assessment.

Authors:  Michael H Davidson
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-09       Impact factor: 8.311

3.  Cardiovascular magnetic resonance measurement of coronary arterial blood flow at rest and after submaximal exercise.

Authors:  Erica Dall'Armellina; Miranda B Baugh; Timothy M Morgan; Craig A Hamilton; Ping Tan; David M Herrington; Kerry M Link; W Gregory Hundley
Journal:  J Comput Assist Tomogr       Date:  2006 May-Jun       Impact factor: 1.826

4.  Conjugated equine estrogens and peripheral arterial disease risk: the Women's Health Initiative.

Authors:  Judith Hsia; Michael H Criqui; David M Herrington; Joann E Manson; Lieling Wu; Susan R Heckbert; Matthew Allison; Mary McGrae McDermott; Jennifer Robinson; Kamal Masaki
Journal:  Am Heart J       Date:  2006-07       Impact factor: 4.749

5.  Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause.

Authors:  Jacques E Rossouw; Ross L Prentice; JoAnn E Manson; Lieling Wu; David Barad; Vanessa M Barnabei; Marcia Ko; Andrea Z LaCroix; Karen L Margolis; Marcia L Stefanick
Journal:  JAMA       Date:  2007-04-04       Impact factor: 56.272

6.  Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease.

Authors:  Joseph Yeboah; David M Reboussin; David Waters; Glenn Kowalchuk; David M Herrington
Journal:  Am Heart J       Date:  2007-03       Impact factor: 4.749

7.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.

Authors:  S Hulley; D Grady; T Bush; C Furberg; D Herrington; B Riggs; E Vittinghoff
Journal:  JAMA       Date:  1998-08-19       Impact factor: 56.272

8.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.

Authors: 
Journal:  N Engl J Med       Date:  1998-11-05       Impact factor: 91.245

9.  Lipoprotein particle concentrations may explain the absence of coronary protection in the women's health initiative hormone trials.

Authors:  Judith Hsia; James D Otvos; Jacques E Rossouw; LieLing Wu; Sylvia Wassertheil-Smoller; Susan L Hendrix; Jennifer G Robinson; Bernedine Lund; Lewis H Kuller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-03       Impact factor: 8.311

10.  Estrogen therapy and coronary-artery calcification.

Authors:  Joann E Manson; Matthew A Allison; Jacques E Rossouw; J Jeffrey Carr; Robert D Langer; Judith Hsia; Lewis H Kuller; Barbara B Cochrane; Julie R Hunt; Shari E Ludlam; Mary B Pettinger; Margery Gass; Karen L Margolis; Lauren Nathan; Judith K Ockene; Ross L Prentice; John Robbins; Marcia L Stefanick
Journal:  N Engl J Med       Date:  2007-06-21       Impact factor: 91.245

View more
  3 in total

Review 1.  Exercise cardiovascular magnetic resonance: development, current utility and future applications.

Authors:  Thomas P Craven; Connie W Tsao; Andre La Gerche; Orlando P Simonetti; John P Greenwood
Journal:  J Cardiovasc Magn Reson       Date:  2020-09-10       Impact factor: 5.364

2.  Endothelial relaxation mechanisms and oxidative stress are restored by atorvastatin therapy in ovariectomized rats.

Authors:  Izabela Facco Caliman; Aline Zandonadi Lamas; Polyana Lima Meireles Dalpiaz; Ana Raquel Santos Medeiros; Glaucia Rodrigues Abreu; Suely Gomes Figueiredo; Lara Nascimento Gusmão; Tadeu Uggere Andrade; Nazaré Souza Bissoli
Journal:  PLoS One       Date:  2013-11-21       Impact factor: 3.240

3.  17β-estradiol reduces Cav 1.2 channel abundance and attenuates Ca2+ -dependent contractions in coronary arteries.

Authors:  Brent J F Hill; Robin J Dalton; Biny K Joseph; Keshari M Thakali; Nancy J Rusch
Journal:  Pharmacol Res Perspect       Date:  2017-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.